Finland· FI-REL-REL28128
Lariam
A mefloquine product containing mefloquine hydrochloride, registered in Finland by Paranova Oy. The same ATC class is registered in 9 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Mefloquine is registered in 9 of 19 countries.
Countries holding a registration under ATC P01BC02 (mefloquine), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 5 of them publish a price we can compare per daily dose
Mefloquine · ATC P01BC02
9 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Mefloquine hydrochloride
- Manufacturer
- Paranova Oy
- Country
- Finland (FI)
- ATC code
- P01BC02
- ATC class
- Mefloquine
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
439 interactions on record for mefloquine.
Graded by severity as the source publishes them — 82 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mefloquine · interactions on record
439 records
- 82 severe
- 338 moderate
- 8 minor
- 11 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- ProcainamideC01BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mefloquine in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsLariam 250 mg, tablettenMedcor Pharmaceuticals B.V.
- United KingdomLariam 250mg tabletsSigma Pharmaceuticals Plc
- United StatesMefloquine HydrochlorideTeva Pharmaceuticals USA, Inc.
- FranceLARIAM 250 mg, comprimé sécableCHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
- NorwayLariamCheplapharm Arzneimittel GmbH
- SwedenLariam 250 mg TablettCheplapharm Arzneimittel GmbH
- CanadaMEFLOQUINEAA PHARMA INC
- SwitzerlandMephaquin, FilmtablettenMepha Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Austria · Lariam
- Belgium · Lariam
- Cyprus · Eloquine
- France · Lariam
- United Kingdom (Northern Ireland) · Lariam, Mefloquine
- Italy · Lariam
- Luxembourg · Lariam
- Netherlands · Lariam
- Norway · Lariam
- Portugal · Mephaquin Lactab
- Sweden · Lariam
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1f96824d-3448-4839-8023-0d1f32fbd4fb GET /v1/drugs/1f96824d-3448-4839-8023-0d1f32fbd4fb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "1",
"form": "tabletti",
"route": "Suun kautta",
"ddd_unit": "g",
"strength": "250 mg",
"atc_label": "meflokiini",
"ma_number": "23303",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL28128",
"authorised_at": "2008-02-25"
}See everything about mefloquine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.